| Gracemed Clearwater Family Clinic | |
|
101 E Ross St Clearwater KS 67026-7824 | |
| (316) 866-2000 | |
| Not Available |
| Full Name | Gracemed Clearwater Family Clinic |
|---|---|
| Speciality | Clinic/Center |
| Location | 101 E Ross St, Clearwater, Kansas |
| Authorized Official Name and Position | Venus Lee (CEO) |
| Authorized Official Contact | 3168662064 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Gracemed Clearwater Family Clinic 1122 N Topeka St Wichita KS 67214-2810 Ph: (316) 866-2000 | Gracemed Clearwater Family Clinic 101 E Ross St Clearwater KS 67026-7824 Ph: (316) 866-2000 |
| NPI Number | 1568947737 |
|---|---|
| Provider Enumeration Date | 10/03/2018 |
| Last Update Date | 02/01/2022 |
| Medicare PECOS PAC ID | 9830098185 |
|---|---|
| Medicare Enrollment ID | O20181018002317 |
News Archive
Future pandemics will emerge more often, spread more rapidly, do more damage to the world economy and kill more people than COVID-19 unless there is a transformative change in the global approach to dealing with infectious diseases, warns a major new report on biodiversity and pandemics by 22 leading experts from around the world.
Astellas Pharma Inc. announced today the completion of its tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc..
Patients with ulcerative colitis have higher rates of sick leave or disability pension than the general population, show findings published in Gastroenterology.
In an opinion piece on the Medecins Sans Frontieres (MSF) website, MSF International President Unni Karunakara writes that with the cancellation of the Global Fund To Fight AIDS, Tuberculosis and Malaria's Round 11 grants, "The Board of the Global Fund must raise the alarm. Instead of accepting rationing, and cancelling ambitions, we urge the Global Fund Board to organize an emergency donor conference to renew commitment and allow countries where the diseases are endemic to apply for funding in 2012."
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568947737 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
Future pandemics will emerge more often, spread more rapidly, do more damage to the world economy and kill more people than COVID-19 unless there is a transformative change in the global approach to dealing with infectious diseases, warns a major new report on biodiversity and pandemics by 22 leading experts from around the world.
Astellas Pharma Inc. announced today the completion of its tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc..
Patients with ulcerative colitis have higher rates of sick leave or disability pension than the general population, show findings published in Gastroenterology.
In an opinion piece on the Medecins Sans Frontieres (MSF) website, MSF International President Unni Karunakara writes that with the cancellation of the Global Fund To Fight AIDS, Tuberculosis and Malaria's Round 11 grants, "The Board of the Global Fund must raise the alarm. Instead of accepting rationing, and cancelling ambitions, we urge the Global Fund Board to organize an emergency donor conference to renew commitment and allow countries where the diseases are endemic to apply for funding in 2012."
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
› Verified 1 days ago
Clearwater Family Practice Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 E Ross St, Clearwater, KS 67026 Phone: 620-584-2055 Fax: 620-584-2032 |